We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Chronic Rhinosinusitis

News List

AZ Fasenra shows benefit in chronic rhinosinusitis with nasal polyps pharmatimes
September 14, 2020
AstraZeneca’s Fasenra (benralizumab) significantly reduced the size of nasal polyps and cut nasal blockage in patients with chronic rhinosinusitis, raising hopes for a new treatment option for this condition.
FDA approves first treatment for chronic rhinosinusitis with nasal polyps biospectrumasia
June 28, 2019
Patients who received Dupixent had statistically significant reductions in their nasal polyp size and nasal congestion compared to the placebo group
FDA Approves Dupixent® for Chronic Rhinosinusitis with Nasal Polyposis americanpharmaceuticalreview
June 27, 2019
The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for use with other medicines to treat chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not controlled. CRSwNP can be a debilitating condition ...